Navigation Links
Ridge Diagnostics Wins Growth-Promoting Loan From Biotech Center
Date:7/10/2009

RESEARCH TRIANGLE PARK, N.C., July 10 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company with a first-in-class, proprietary blood test for Major Depressive Disorder (MDD), announced the award of a $202,500 loan from the North Carolina Biotechnology Center. The funds will further develop the company's CLIA certified laboratory in Research Triangle Park, thereby supporting the commercialization of its proprietary blood test for depression.

The award was made under the Biotechnology Center's Strategic Growth Loan (SGL) program, which helps promising North Carolina companies succeed in the challenging startup process.

"Ridge Diagnostics is a great example of why the loans from the North Carolina Biotechnology Center are so important," said John Richert, vice president for business and technology development at the North Carolina Biotechnology Center. "By helping them advance their technologies, we enable a strong company to grow stronger, bringing economic opportunity and the prospect of new jobs to the state."

This is the second SGL awarded to Ridge. The company is preparing to launch its multi-analyte blood test for diagnosing clinical depression and monitoring its therapy. The MDDScore(TM) provides objective, biological information associated with physiological changes caused by the condition. The test will be used by physicians to augment traditional diagnostic tools such as behavioral questionnaires and clinical assessments.

"Ridge Diagnostics, once again, would like to thank the NC Biotechnology Center for their ongoing support of the company," said Stan Sewitch, CEO. "By preparing our laboratory for commercial expansion, this Strategic Growth Loan allows us to offer our Clinical Experience Program to physicians and patients in North Carolina and other select areas of the United States."

The Ridge Clinical Experience Program, slated to begin in September, will enable practicing physicians to experience the benefits of the test as an aid in the diagnosis and management of patients with depression.

Ridge Diagnostics, Inc. is a neurodiagnostic company commercializing a breakthrough first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The company's products are based on a proprietary Human Biomarker Library and Hyper-Mapping(TM) analytical technology. Ridge intends to develop a comprehensive program of neuropsychiatric disease diagnostics. Ridge Diagnostics' tests are provided through its CLIA certified laboratory in North Carolina, with plans for diagnostic test kits sold worldwide. The company's research and clinical laboratories are headquartered in Research Triangle Park, NC, with administrative offices in San Diego, CA. www.RidgeDx.com

About the North Carolina Biotechnology Center

The Biotechnology Center, headquartered in Research Triangle Park, is a private, non-profit corporation supported by the NC General Assembly. Its mission is to provide long-term economic and societal benefits to North Carolina by supporting biotechnology research, business, education and strategic policy statewide.


'/>"/>
SOURCE Ridge Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
2. Massachusetts Employers and Health Plans Continue to Support Quality Care by Rewarding Physicians through Bridges to Excellence Programs
3. EPA Says Follow-Up Sampling Shows No PCB Risk at Park Ridge Elementary School
4. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
5. The Cambridge Group Names Two New Principals
6. Story tips from the Department of Energys Oak Ridge National Laboratory, Nov. 2007
7. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
8. Bridges to Excellence Announces New Implementation Programs for Health Plans and Additions to Board of Directors
9. Audio from Medialink and GlaxoSmithKline: Cleaning House ... Overhaul Your Fridge and Pantry to Lose Weight
10. Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
11. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care Academy at Kalamazoo ... Students who successfully complete the seven-week long Patient Care Academy are eligible to take ... starting salary for a CNA in Kalamazoo is $24,428.* , As a CNA, one ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Greenfield Advisors is ... in the U.S. for the second year in a row. The Inc. 5000 list ... three years. , “To be on the list once is a great accomplishment, but ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... list represents a unique look at the most successful companies within the American economy’s ...
(Date:8/16/2017)... York, New York (PRWEB) , ... August 16, 2017 , ... ... they could minimize its appearance with diet and exercise. In fact, cellulite can't always ... is a safer and more effective treatment available to select physicians nationwide. Dr. Kenneth ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Maury Regional ... starts and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is ... of the guesswork out of a needle stick and more importantly, helps our staff ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: